Results 141 to 150 of about 6,141,684 (256)

Is There Still a Role for Autologous Stem Cell Transplantation in Older Adults with AML? [PDF]

Hematol Rep
Capria S, Minotti C, Breccia M, Bisegna ML, Carmosino I, Chiusolo P, Di Marino L, Luzi G, Mariani S, Marsili G, Marabitti L, Ortu La Barbera E, Scollo L, Martelli M, Trisolini SM.   +14 more
europepmc   +1 more source

Cardio-Oncological Sequelae of Autologous Stem Cell Transplantation: Role of Clonal Hematopoiesis in Cardiovascular Risk. [PDF]

JACC Adv
Sándor Z, Varga ZV, Gergely TG, Horváth L, Masszi T, Drobni ZD, Fuster JJ, Pozsonyi Z.   +7 more
europepmc   +1 more source

Neural stem cells, neural progenitors, and neurotrophic factors

, 2008
[[abstract]]Neural stem cells (NSCs) have been proposed as a promising cellular source for the treatment of diseases in nervous systems. NSCs can self-renew and generate major cell types of the mammalian central nervous system throughout adulthood.
Hsu, YC; Lee, DC; Chiu, IM
core  

Dynamic risk stratification using early CAR‐T expansion in R/R LBCL treated with axicabtagene ciloleucel

British Journal of Haematology, EarlyView.
Higher chimeric antigen receptor‐T expansion at day 7 is associated with improved progression‐free survival but also increased toxicity in axi‐cel treated patients with R/R large B‐cell lymphoma, independent of other baseline patient and disease characteristics.
Brydon Panozzo, Samuel Robinson, Adrian G. Minson, Jian Li, Kylie Baldwin, Hamish W. Scott, Jane Oliaro, Aaron J. N. Wong, Samantha van der Linde, Nicole L. O'Leary, Philip A. Thompson, John F. Seymour, Mary Ann Anderson, Constantine S. Tam, Simon J. Harrison, Michael J. Dickinson, David A. Westerman, Mark R. Dowling   +17 more
wiley   +1 more source

Narrative nursing for prolonged myelosuppression after autologous stem cell transplantation in multiple myeloma: A case report. [PDF]

Medicine (Baltimore)
Huang Q, Jiang M.
europepmc   +1 more source

A phase IIa study of the anti‐PD‐L1 antibody avelumab in relapsed/refractory PTCL: The AVAIL‐T trial

British Journal of Haematology, EarlyView.
The AVAIL‐T study, the first evaluation of programmed death ligand 1 (PD‐L1) blockade in relapsed/refractory peripheral T‐cell lymphomas (PTCL), demonstrated limited single agent activity with durable responses seen in a minority. Circulating tumour DNA revealed distinct mutational dynamics and mass cytometry identified perturbed T‐cell subsets ...
Matthew J. Ahearne, Matthew A. Timmins, Charlotte Gaskell, Aimee Jackson, Clare Morland, Sonia Fox, Louise Hopkins, Nadia Nawaz, Susann Lehmann, Marc Wadsley, Caroline Cowley, Jacqueline Shaw, Naeem Khan, Nagesh Kalakonda, Christopher Trethewey, Ram Malladi, Paul Fields, Dima El Sharkawi, Michael Quinn, Nimish Shah, Andrew Davies, Kim Linton, Pam McKay, Rod Johnson, Simon D. Wagner, David Lewis, Graham P. Collins, Christopher P. Fox, Kate Cwynarski   +28 more
wiley   +1 more source

CAR‐HEMATOTOX score to predict risk of poor outcomes with odronextamab in heavily pretreated B‐cell non‐Hodgkin lymphoma

British Journal of Haematology, EarlyView.
High versus low baseline CAR‐HEMATOTOX scores were associated with poorer safety and efficacy outcomes in patients with R/R B‐NHL who received odronextamab in the ELM‐1 and ELM‐2 studies. The CAR‐HEMATOTOX score may provide a readily available measure for identifying patients at risk of inferior clinical outcomes with odronextamab treatment.
Matthew Matasar, David Tucker, Tae Min Kim, Yuan Cheng, Jingjin Li, Saleem Shariff, Hesham Mohamed, Manjusha Namuduri, Aafia Chaudhry, Stefano Luminari   +9 more
wiley   +1 more source

Engraftment Syndrome After Second Autologous Stem Cell Transplantation for Myeloma: A Case Report. [PDF]

Case Rep Hematol
Salveridou K, Tzamalis T, Klaiber-Hakimi M, Haase S, Diederich S, Giagounidis A.   +5 more
europepmc   +1 more source

Chemical injury treated with autologous limbal epithelial stem cell transplantation and subconjunctival bevacizumab

, 2014
Gian Maria Cavallini,1 Graziella Pellegrini,2 Veronica Volante,1 Pietro Ducange,1 Michele De Maria,1 Giulio Torlai,1 Caterina Benatti,1 Matteo Forlini1 1Institute of Ophthalmology, 2Centre for Regenerative Medicine “Stefano Ferrari&rdquo ...
De Maria M, Benatti C, Cavallini GM, Pellegrini G, Ducange P, Torlai G, Forlini M, Volante V   +7 more
core  

Temporal trends in infectious risk among multiple myeloma patients treated with daratumumab: A meta‐analysis

British Journal of Haematology, EarlyView.
Summary Anti‐cluster of differentiation 38 (Anti‐CD38) monoclonal antibodies such as daratumumab are widely used in multiple myeloma (MM), yet the timing and magnitude of infectious risk remain incompletely defined. We performed an individual patient‐level meta‐analysis of six randomized trials (N = 2989) comparing daratumumab‐ versus non‐daratumumab ...
Alissa Visram, Hira Mian, James Lee, Aaron Jones, Gregory R. Pond, Doris Hansen, Surbhi Sidana, Luciano J. Costa   +7 more
wiley   +1 more source